BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 12139425)

  • 1. Resistance mechanisms of gram-positive bacteria.
    Berger-Bächi B
    Int J Med Microbiol; 2002 Jun; 292(1):27-35. PubMed ID: 12139425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial resistance in gram-positive bacteria.
    Rice LB
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S11-9; discussion S64-73. PubMed ID: 16813977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial resistance in gram-positive bacteria.
    Rice LB
    Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens.
    Witte W; Cuny C; Klare I; Nübel U; Strommenger B; Werner G
    Int J Med Microbiol; 2008 Jul; 298(5-6):365-77. PubMed ID: 18325835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current challenges in antibiotic resistance.
    Hand WL
    Adolesc Med; 2000 Jun; 11(2):427-38. PubMed ID: 10916132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gram-positive bacterial infections resistant to antibiotic treatment].
    Utili R
    Ann Ital Med Int; 2001; 16(4):205-19. PubMed ID: 11799629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiology and drug resistance mechanisms of fully resistant pathogens.
    Walsh FM; Amyes SG
    Curr Opin Microbiol; 2004 Oct; 7(5):439-44. PubMed ID: 15451497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fighting infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G
    Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus.
    Cunha BA
    Med Clin North Am; 2006 Nov; 90(6):1165-82. PubMed ID: 17116442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infections caused by Gram-positive bacteria: a review of the global challenge.
    Woodford N; Livermore DM
    J Infect; 2009 Sep; 59 Suppl 1():S4-16. PubMed ID: 19766888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of antibiotic-resistant Gram-positive pathogens.
    Lode HM
    Clin Microbiol Infect; 2009 Mar; 15(3):212-7. PubMed ID: 19335368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics of glycopeptide resistance in gram-positive pathogens.
    Courvalin P
    Int J Med Microbiol; 2005 Mar; 294(8):479-86. PubMed ID: 15790292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
    Li JT; Li Y; Wang J;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of antimicrobial susceptibility patterns of gram-positive bacteria from National Antimicrobial Resistance Surveillance Thailand (NARST) program from 2000 to 2005.
    Mootsikapun P; Trakulsomboon S; Sawanpanyalert P; Aswapokee N; Suankratay C
    J Med Assoc Thai; 2009 Aug; 92 Suppl 4():S87-90. PubMed ID: 21294504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
    Carpenter CF; Chambers HF
    Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
    Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
    Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010.
    Nordmann P; Naas T; Fortineau N; Poirel L
    Curr Opin Microbiol; 2007 Oct; 10(5):436-40. PubMed ID: 17765004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.